www.marketwatch.com Open in urlscan Pro
108.139.47.14  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main content

Advertisement
Subscribe Now: $8 per Month
 * Home
 * Latest News
 * Watchlist
 * Market Data Center
    * U.S.
    * Cryptocurrency
    * Europe
    * Rates
    * Asia
    * Futures
    * Currencies

 * Markets
    * U.S. Markets
    * Canada
    * Europe & Middle East
    * Asia
    * Emerging Markets
    * Latin America
    * Market Data

 * Investing
    * Barron's
    * Best New Ideas
    * Stocks
    * IPOs
    * Mutual Funds
    * ETFs
    * Options
    * Bonds
    * Commodities
    * Currencies
    * Cryptocurrencies
    * Futures
    * Financial Adviser Center
    * Cannabis
    * Newswires

 * Barron's
 * Economy & Politics
    * Washington Watch
    * Inflation
    * Coronavirus
    * The Federal Reserve
    * Economic Report
    * Rex Nutting
    * U.S. Economic Calendar
    * Coronavirus Recovery Tracker

 * Personal Finance
    * The Moneyist
    * Spending & Saving
    * Retirement
    * TaxWatch
    * Credit Cards
    * Careers
    * Travel
    * Real Estate
    * Real Estate Listings

 * Retirement
    * Best New Ideas in Retirement
    * Estate Planning
    * Help Me Retire
    * FIRE
    * Taxes
    * Social Security
    * Real Estate
    * Retirement Calculator
    * NewRetirement Planner
    * Where Should I Retire
    * Best Places

 * How to Invest
 * Virtual Stock Exchange
 * Video
    * MarketWatch 25 Years
    * SectorWatch
    * The Moneyist
    * Getting to Work With
    * Explainomics
    * How to Invest
    * MarketBrief
    * Fire Starters
    * How Bad Is It
    * The Cost of Things
    * Office Hours
    * Best New Ideas in Money Festival
    * Mastering Your Money

 * Podcasts
 * Live Events
 * Opinion
 * Investor's Business Daily
    * Leaderboard
    * SwingTrader
    * MarketSmith
    * IBDLive

 * Newsletter Center
 * Research & Tools
    * Watchlist
    * Mortgage Calculator
    * Multiple Quotes Tool
    * Stock Screener
    * Earnings Calendar
    * Market Screener
    * IPO Calendar
    * Short Interest
    * Premarket Screener
    * Options Expiration Calendar
    * After Hours Screener
    * Currency Tools
    * Mutual Fund Screener
    * Upgrades & Downgrades
    * Top 25 Mutual Funds
    * Mutual Fund Comparison
    * Economic Calendar
    * Where Should I Retire?
    * Retirement Planner
    * Top 25 ETFs

 * MarketWatch Picks
    * Loans
    * Money
    * Technology
    * Real Estate
    * Guides
    * Credit Cards
    * Banking
    * Lifestyle
    * Investing

Sign Up Log In
 * Profile Settings
 * Watchlist
 * Email & Alerts
 * Games

MW Anniversary Logo Go to the homepage.
 * Latest
 * Watchlist
 * Markets
 * Investing
 * Personal Finance
 * Economy
 * Retirement
 * How to Invest
 * Video Center
 * Live Events
 * MarketWatch Picks
 * More
   Latest Watchlist Markets Investing Personal Finance Economy Retirement How to
   Invest Video Center Live Events MarketWatch Picks

$8 per Month
 * Account Settings
 * Log In
 * Sign Up

Close Search Overlay


Advertisement

Advertisement

 1. Home
 2. Industries
 3. Health Care
 4. Coronavirus Update


CORONAVIRUS UPDATE




HOSPITALIZATIONS ON THE RISE IN NEW YORK CITY AS NEW COVID STRAINS SPREAD
RAPIDLY

Published: Nov. 1, 2022 at 10:37 a.m. ET
By

CIARA LINNANE

  comments


PFIZER RAISES GUIDANCE FOR COVID VACCINES AND STILL EXPECTS $22 BILLION IN SALES
FOR ITS ANTIVIRAL THIS YEAR

A MAN OUTSIDE A COVID TESTING FACILITY IN THE BRONX IN NEW YORK CITY, WHERE
HOSPITALIZATIONS ARE RISING AGAIN.

timothy a. clary/Agence France-Presse/Getty Images
 * Email icon
 * Facebook icon
 * Twitter icon
 * Linkedin icon
 * Flipboard icon

 * Print icon
 * Resize icon


REFERENCED SYMBOLS


Advertisement
PFE
+1.40%
AAPL
-0.19%
2317
-0.50%
AZN
+1.77%
AZN
+0.56%

Your browser does not support the audio tag.
Listen to article
Length 6 minutes
AD
Loading advertisement...
00:00 / 05:45
1x

This feature is powered by text-to-speech technology. Want to see it on more
articles?
Give your feedback below or email audiofeedback@marketwatch.com.
thumb-stroke-mediumthumb-stroke-medium

Hospitalizations are rising again in New York City with the spread of new
COVID-19 subvariants that are better at evading immunity. Cases of flu and
respiratory syncytial virus, or RSV, are also increasing.

State data show about 1,100 patients hospitalized with COVID as of Oct. 24, up
from 750 in mid-September, as the New York Times reported. Case numbers have
held steady, although with many people testing at home where data are not being
collected, those numbers are not reliable.

Data from the Centers for Disease Control and Prevention show that the omicron
sublineages named BQ.1 and BQ.1.1 accounted for 42.5% of all cases in the New
York region in the week through Oct. 29, up from 37% the previous week.


Advertisement

That was more than the BA.5 omicron subvariant, which accounted for 35.7% of new
cases in the New York region in the latest week. The two sublineages were not
even registering as recently as three weeks ago, demonstrating just how fast
they are spreading.



Experts are also concerned about a nationwide surge in RSV, which can cause
breathing difficulties in small children and older adults and for which there is
currently no vaccine.

There was good news from Pfizer Inc., however, which said Tuesday that data from
a late-stage trial of an RSV vaccine had proved effective in preventing severe
illness in children up to 6 months old.

Now Playing: New Signs of Weakness

1/1 Skip Ad Continue watching after the ad Visit Advertiser websiteGO TO PAGE

NEXT Off English 360p 720p HD 1080p HD Auto (360p) About Connatix V196709 About
Connatix V196709
Visit our Video Center

The Phase 3 trial found that the vaccine, given to pregnant mothers, achieved
vaccine efficacy of 81.8% in infants from birth through the first 90 days of
life. The trial found efficacy of 69.4% through the first 6 months of life.

Pfizer PFE, +1.40% said it expects to make its first U.S. regulatory application
for the vaccine by the end of 2022 and to follow on with other regulatory
bodies. It will also submit the results of the trial for peer review in a
scientific journal.

The daily U.S. average for new COVID cases stood at 37,665 on Monday, according
to a New York Times tracker, which was flat as compared with two weeks ago. The
daily average for hospitalizations was up 2% to 27,184, while the daily average
for deaths was down 3% to 348. 

Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting
all the latest developments every weekday since the coronavirus pandemic began


VOLATILITY IS TEMPORARY. FINANCIAL FREEDOM IS FOREVER.

Understand how today’s business practices, market dynamics, tax policies and
more impact you with real-time news and analysis from MarketWatch.

Subscribe Now: $8 per Month


Other COVID-19 news you should know about:

• Apple  AAPL, -0.19% supplier Foxconn 2317, -0.50% said Tuesday it has
quadrupled bonuses for workers at its Zhengzhou plant in central China as it
seeks to quell discontent over COVID restrictions and retain staff at the giant
iPhone manufacturing site, Reuters reported. Daily bonuses for employees, who
are part of a Foxconn unit responsible for making electronics including
smartphones, have been raised to 400 yuan ($55) a day for November from 100
yuan, according to the official WeChat account of Foxconn’s Zhengzhou plant. The
move comes after workers fled the site over the weekend to avoid COVID curbs
after complaining about their treatment and provisions via social media.

Workers Flee Foxconn’s Covid-Hit iPhone Factory, Disrupting Production
You may also like

CloseCreated with sketchtool.
Up Next
CloseCreated with sketchtool.

Your browser does not support HTML5 video.

0:00
ADVERTISEMENT
0:00

PlayCreated with sketchtool.
Paused
Sound OnCreated with sketchtool.

0:00 / 2:25


ShareCreated with sketchtool.Closed Captions InactiveCreated with sketchtool.
Workers Flee Foxconn’s Covid-Hit iPhone Factory, Disrupting Production Play
video: Workers Flee Foxconn’s Covid-Hit iPhone Factory, Disrupting Production
Workers at the world’s biggest assembly site for Apple’s iPhones walked out as
Foxconn has struggled to contain a COVID-19 outbreak. The chaos highlights the
tension between Beijing’s rigid pandemic controls and the urge to keep
production on track. Photo: Hangpai Xinyang/Associated Press

• The Wall Street Journal reported Tuesday that Hong Kong stocks appeared to be
rallying after an anonymous post on Chinese social media suggested that the
government may intend to soften pandemic-related restrictions beginning in
March. Other outlets also reported on the rumor. American depositary receipts
for Chinese companies surged on the news.


Advertisement

See: Alibaba and Nio among Chinese stocks surging as hopes build about potential
reopening

• Pfizer’s COVID antiviral Paxlovid brought in $7.5 billion in sales in
the third quarter of the year, compared with a FactSet consensus of $7.6
billion. The drug company also reiterated guidance for Paxlovid revenues in
2022, saying it still expects $22 billion in sales for the year. The FactSet
consensus is $22.5 billion. Pfizer raised its full-year revenue guidance for the
company’s Comirnaty COVID vaccine by $2 billion to $34 billion. The guidance
includes doses expected to be delivered in fiscal 2022, primarily under
contracts signed as of mid-October.

• AstraZeneca PLC’s AZN, +1.77% AZN, +0.56% COVID vaccine Vaxzevria has been
granted full marketing authorization in the European Union, Dow Jones Newswires
reported. The Anglo-Swedish pharmaceutical giant said Vaxzevria has been shown
to be effective against all forms of the virus. Vaxzevria was originally granted
conditional marketing authorization due to the urgency of the COVID-19 pandemic,
it said.

Here’s what the numbers say:

The global tally of confirmed cases of COVID-19 topped 630.6 million on Monday,
while the death toll rose above 6.59 million, according to data aggregated by
Johns Hopkins University.

The U.S. leads the world with 97.5 million cases and 1,070,429 fatalities.

The Centers for Disease Control and Prevention’s tracker shows that 226.9
million people living in the U.S., equal to 68.4% of the total population, are
fully vaccinated, meaning they have had their primary shots.

So far, just 22.8 million Americans have had the updated COVID booster that
targets the original virus and the omicron variants, equal to 7.3% of the
overall population.



Advertisement

PARTNER CENTER


Advertisement

Advertisement

Advertisement

Advertisement

MOST POPULAR


Advertisement

‘FREE-SPEECH ABSOLUTIST’ ELON MUSK CRACKS DOWN ON PARODY ACCOUNTS TARGETING HIM

APPLE WARNS THAT IPHONE 14 PRO AND PRO MAX SHIPMENTS WILL BE AFFECTED BY CHINA
PRODUCTION ISSUES

‘HE’S NOT WILLING TO LIVE IN MY HOUSE BECAUSE IT HAS FEWER AMENITIES’: MY
BOYFRIEND WANTS ME TO MOVE IN AND PAY HALF HIS MONTHLY COSTS. IS THAT FAIR?

STEVE CASE SAYS, 'IN FIVE YEARS, THERE WON'T EVEN BE A TECH SECTOR'

‘LOVE YOURSELF AND PROTECT YOURSELF’: I CARE FOR MY MOTHER, 90, AND HUSBAND, 73.
HE CONTRIBUTES NOTHING. I WORK AND PAY ALL THE BILLS. WHAT HOPE DO I HAVE?


Advertisement


Advertisement


READ NEXT


READ NEXT


BARRON'S: POWERBALL GRAND PRIZE IS NOW $1.9 BILLION. HERE’S WHAT THE WINNER
COULD BUY.

The jackpot's lump-sum cash payout would be an estimated $929.1 million, which
could fund the four-year cost of a Harvard University undergraduate education
for 2,894 students.


MORE ON MARKETWATCH

 * Amazon stock breaks long-term chart support, closes in on big inflection
   point
 * Barron's: Stocks Poised to Fall on Monday
 * Food prices keep rising. Food-company execs are betting Americans will keep
   paying.
 * Pfizer-BioNTech bivalent booster shows higher immune response, but new COVID
   cases climb back above 40,000 a day


ABOUT THE AUTHOR

Ciara Linnane


Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is
based in New York.

SmartAsset.com
Community Guidelines • FAQs

Advertisement


PARTNER CONTENT




PARTNER CONTENT



Back to Top
MW Anniversary LogoGo to the homepage
Copyright © 2022 MarketWatch, Inc. All rights reserved.
By using this site you agree to the Subscriber Agreement & Terms of Use, 
Privacy Notice, and Cookie Notice.
 * Facebook
 * Twitter
 * Linkedin
 * 

 * MARKETWATCH

 * Customer Center
 * Contact Us
 * Newsroom Roster
 * Virtual Stock Exchange
 * BigCharts
 * Copyright Policy
 * Manage Notifications

 * COMPANY

 * Dow Jones
 * Code of Conduct
 * Corrections
 * Reprints & Licensing
 * Digital Self Service
 * Your Ad Choices
 * Corporate Subscriptions
 * Accessibility

 * DOW JONES NETWORK

 * The Wall Street Journal
 * Barron's
 * Financial News London
 * realtor.com
 * Mansion Global

Intraday Data provided by FACTSET and subject to terms of use. Historical and
current end-of-day data provided by FACTSET. All quotes are in local exchange
time. Real-time last sale data for U.S. stock quotes reflect trades reported
through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange
requirements.

You are approaching your article limit.
Get unlimited access for $8 per month


Search Clear

Search
Advanced Search

Advertisement


SEARCH RESULTS

All News
Articles
Video
Podcasts






AUTHORS




SECTIONS




COLUMNS




SYMBOLS




PRIVATE COMPANIES




RECENTLY VIEWED TICKERS


NO RECENT TICKERS

Visit a quote page and your recently viewed tickers will be displayed here.

Search Tickers




No results found

No results found